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Abstract: The number of fatalities due to cardiovascular disease (CVD) continues to be far ahead of loss of human life caused 
by any other type of disease worldwide. According to the WHO, the annual global tobacco death toll is already 8.4 million 
and will reach 10 million by the year 2025. However, in contrast to other modiﬁ  able primary risk factors for CVD such as 
obesity, primary prevention strategies for smokers unable to quit are not available to date. This Review, by adopting the prin-
ciples of evidence-based medicine, summarizes the most recent clinical studies on CVD in smokers, and concludes by sug-
gesting a novel primary prevention strategy for CVD in smokers unable to quit. Evidence gathered from mechanistic studies 
involving basic research as well as large population-based approaches point to oxidative stress as the major insult imposed 
by cigarette smoke (CS), and a state of systemic inﬂ  ammation, as signiﬁ  ed by increased hs (high sensitivity) CRP levels in 
smokers, as the decisive pro-atherogenic response of the body to the initial insult. Since we identiﬁ  ed oxidative stress induced 
by heavy metals as a signiﬁ  cant pro-atherogenic activity of CS, strategies aimed at detoxifying heavy metals and combating 
inﬂ  ammation appear as plausible approaches to counteract the accelerated onset of CVD in smokers. For this purpose, we 
discuss metal chelating agents and statins as promising novel primary prevention strategies in smokers unable to quit.
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Introduction
Smoking remains a major cause of cardiovascular disease (CVD)-related morbidity and mortality. The 
prediction of the WHO that by 2020 smoking will be the largest single health problem worldwide indi-
cates the magnitude of burden that can be expected to be imposed on the health care system by smoking-
associated morbidities. Considerable governmental efforts aimed at deterring people from cigarette 
smoke (CS) consumption have been put into action, and indeed western societies are now experiencing 
for the ﬁ  rst time a situation in which the prevalence of smoking is on the decline. Despite this fortunate 
development, however, the percentage of young people who smoke remains at a high level, and the 
prevalence of smokers worldwide is still rising rapidly. Our ﬁ  nding that smoking constitutes the most 
signiﬁ  cant risk factor for the development of early atherosclerosis in young people (Knoﬂ  ach and others, 
2003) highlights the urgent need to reinforce preventive strategies aimed at reducing CS consumption. 
At the same time, robust biomarkers for identiﬁ  cation of individuals at high risk for CS-associated 
atherosclerosis and associated cardiovascular events are urgently needed for timely instrumentation of 
primary prevention strategies, given that a vast majority of smokers are unable to quit their habit. Our 
current understanding of the mechanisms by which CS promotes atherogenesis allows targeting different 
types of molecules as possible candidates, the measurements of which can help determine whether there 
is an increased risk for cardiac events. At the same time, the quest for novel molecules that give an even 
more precise account of the presence of the disease and risk for atherosclerotic complications continues 
to proceed at a high pace. However, for a molecule to be considered a risk predictor, it needs to possess 
certain characteristics, especially if it is to be used for routine assessment in the clinical arena (Mosca, 
2002; Pearson and others, 2003), the most important of which include reliable standardization of the 
assay, association with CVD endpoints of clinical relevance, independence from classical risk factors 
and the ability to augment our current prognostic capabilities beyond that achievable by use of traditional 128
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risk stratiﬁ  cation methods. Another important issue 
that needs to be addressed when referring to a 
biomarker for a certain disease is whether it serves 
as a risk marker, i.e. a measure for the disease 
process without any associated causal role, or as a 
risk factor i.e. is causally involved in the disease 
process, as the latter, besides being relevant in 
determining risk, also provides some insights into 
the underlying pathophysiology and potentially 
paves the way for the development of novel thera-
peutic strategies.
Since inﬂ  ammation has been identiﬁ  ed as a 
consistent driving force for all stages of the ath-
erogenic process (Ross, 1999), a host of markers 
for the grade of ongoing inﬂ  ammation have been 
postulated to possess a strong predictive ability for 
the presence of progressing atherosclerotic changes 
in the vascular wall. Most signiﬁ  cantly, inﬂ  amma-
tory markers might indicate ongoing inﬂ  ammation 
at a sub-clinical stage of atherosclerosis, rather 
than a clinically overt phenotype, which allows for 
identiﬁ  cation of a cohort of people that would 
beneﬁ  t from therapeutic and lifestyle intervention 
strategies.
In addition to markers pointing to a pro-
inﬂ  ammatory status, there is a large body of evi-
dence in support of biomarkers indicative of a 
perturbed redox balance in the process of atheroma 
formation. We and others provided evidence for a 
reactive oxygen species (ROS)-mediated patho-
physiological pathway conducive to atherogenesis 
that might have a role to play, in particular, in CS-
mediated CVD (Bernhard and others, 2003; 
Bernhard and others, 2005). Most of these types 
of molecules arise from oxidative modiﬁ  cation of 
various lipid moieties, giving rise to lipid deriva-
tives such as oxysterols, isoprostanes and oxLDL. 
Besides measurement of lipid oxidation products, 
the presence of oxidants such as free radicals and 
heavy metals can be directly determined by electron 
spin resonance (ESR)-spectrometry. In fact, data 
gained in the course of research carried out by our 
group support our working hypothesis that oxidative 
stress, generated by an interplay of metals and ROS, 
has a signiﬁ  cant role to play in the pro-atherogenic 
activity of cigarette smoke extract (CSE) in vitro 
(Bernhard and others, 2003; Bernhard and others, 
2005; Csordas and others, 2006). Moreover, our 
ﬁ  nding of increased heavy metal levels in the serum 
of young smokers enabled extrapolation of our 
in vitro results to the in vivo situation (Bernhard 
and others, 2006).
This review (i) summarizes the most recent data 
on biomarkers for CVD with emphasis on risk 
assessment in chronic smokers, (ii) relates the origin 
of these markers to the underlying pathophysiolog-
ical cascade of events elicited by CS, and 
(iii) discusses the data in relation to our own concept 
of CS-induced atherosclerosis. Finally, (iv) we 
make an attempt to translate this data into a novel 
primary prevention strategy for the large population 
of smokers unable to quit their habit.
Cigarette Smoke Consumption
and Inﬂ  ammation
hsCRP
Evidence gathered from research involving basic 
experimental designs as well as population-based 
observational studies led to the recognition that 
inﬂ  ammatory processes are central to all stages 
of the atherosclerotic disease, with inﬂ  ammation 
being decisive for initiation, progression and 
onset of clinically overt disease (Libby and others, 
2002). Among the various biomarkers that are 
available for measuring ongoing inﬂ  ammation, 
plasma CRP represents the most extensively 
studied one, and has a long history in the clinical 
arena as an acute-phase reactant, the quantiﬁ  ca-
tion of which enables detection of the presence 
of an infectious disease. These clinically applied 
CRP-assays, however, were only able to detect 
massive elevations of circulating CRP and were 
not sensitive enough to accurately measure CRP 
levels in apparently healthy individuals below the 
threshold level that suggest an ongoing infection. 
Development of highly sensitive assays, however, 
ultimately permitted to reliably assess these low 
abundant CRP levels (hsCRP), so that variations 
in the conventional reference ranges of CRP, 
previously considered as normal, are now receiv-
ing increasing recognition as the most promising 
candidate biomarkers of chronic low grade 
inﬂ  ammation and associated risk of cardiac events 
in otherwise healthy people. Initial data sugges-
tive of a potential role of CRP as an independent 
predictor of cardiac events came from the Euro-
pean Concerted Action on Thrombosis and Dis-
abilities (ECAT) study (Anonymous, 1993) that 
established elevated CRP levels as a predictor for 
future coronary events in people with stable and 
unstable angina (Haverkate and others, 1997). 
Notably, this study found markedly elevated 129
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levels of CRP among the smoking participants 
compared to the non-smokers. Later, several 
clinical studies extended these results to cohorts 
without manifest CVD by demonstrating that also 
among subjects with no prior occurrence of isch-
emic heart disease, plasma CRP levels serve as a 
prognostic marker for future cardiovascular 
events. Ridker and colleagues analysed the pre-
dictive capabilities of CRP as related to other 
known risk factors among participants of the 
Physicians’ Health Study and provided evidence 
for an independent predictive role of circulating 
CRP for coronary events and peripheral arterial 
disease in initially healthy subjects (Ridker and 
others, 1997; Ridker and others, 1998a). In 
another cohort of subjects participating in this 
study, hsCRP levels proved to augment the predic-
tive information provided by lipid screening alone 
(Ridker and others, 1998b). An investigation 
involving the Augsburg cohort of the Monitoring 
Trends and Determinants in Cardiovascular Dis-
ease (MONICA) study (Bothig, 1989) evaluated 
the role of CRP in cardiovascular risk prediction 
in initially healthy men on the basis of an 8-year 
follow-up, and conﬁ  rmed the predictive relevance 
of serum CRP levels for occurrence of coronary 
heart disease in subjects without prior cardiac 
disease (Koenig and others, 1999). This study 
concluded that subjects in the highest quintile of 
CRP distribution have a 2.6-fold increased risk 
for future CVD-related outcomes. Also in this 
study, a strong unadjusted correlation of smoking 
with elevated CRP levels was detected. Using 
data from the Women’s Health Study, Ridker et al. 
found that baseline plasma hsCRP constitutes an 
independent risk factor that, in combination with 
plasma LDL, better identiﬁ  es women at increased 
risk for ﬁ  rst cardiovascular events than imple-
mentation of cholesterol screening alone (Ridker 
and others, 2000; Ridker and others, 2002). These 
findings are of particular interest, given that 
almost 50% of cardiovascular events occur in 
individuals with below average plasma levels of 
total cholesterol (Braunwald, 1997), who at pres-
ent are missed by current criteria for instrumenta-
tion of pharmacological therapy and lifestyle 
interventions.
Of note, in a secondary prevention population, 
pravastatin therapy has been shown to lower 
median plasma hsCRP in a manner independent of 
plasma cholesterol levels. Furthermore, risk reduc-
tion for recurrent cardiac events associated with 
statin therapy was more pronounced in individuals 
exhibiting a pro-inﬂ  ammatory state (Ridker and 
others, 1998d; Ridker and others, 1999). Another 
double-blind prospective trial on a primary preven-
tion cohort found that under pravastatin treatment, 
median CRP levels decreased by 16.9% in an LDL-
C independent manner (Albert and others, 2001). 
Conﬁ  rmation of this result was obtained in a pri-
mary prevention cohort by implementation of 
lovastatin therapy in the course of the Air Force/
Texas Coronary Prevention Study (AFCAPS/Tex-
CAPS), as well as by administration of cerivastatin 
to patients with primary hypercholesterolemia—
both drug regimens resulted in a signiﬁ  cant reduc-
tion of plasma CRP levels (Ridker and others, 
2001b). Of note, statin therapy proved to be effec-
tive in reducing risk for ﬁ  rst coronary events in 
subjects with elevated CRP levels in the absence 
of overt hyperlipaemia (Ridker and others, 2001b). 
Interestingly, while there was a clear dose-response 
effect of cerivastatin on LDL-C, such an effect was 
not observed with regard to CRP, with a low-dose 
cerivastatin regimen being associated with a 
prominent reduction of median CRP levels (Ridker 
and others, 2001c). This appears to be a substantial 
ﬁ  nding, as it demonstrates that the anti-inﬂ  ammatory 
effects of statins operate independently of their 
lipid-lowering activity, and that the decline of CRP 
levels is not secondary to statin-mediated modula-
tion of the lipid proﬁ  le. At the same time, these 
data suggest that primary prevention strategies for 
CVD, based on statin treatment, designed as an 
anti-inﬂ  ammatory treatment in people identiﬁ  ed 
as exhibiting a pro-inﬂ  ammatory state might be 
feasible also from an economic point of view, given 
that even moderate doses of statins proved to be a 
successful strategy in combating inﬂ  ammation.
However, it has to be pointed out that the 
overall data on an incremental prognostic infor-
mation of hsCRP beyond that of traditional risk 
factors in predicting ﬁ  rst major cardiovascular 
events are not entirely consistent, and the value 
of CRP as a useful clinical tool for reﬁ  nement of 
the current level of risk prediction has been ques-
tioned by other large observational studies that 
found either no or only a moderate increase in 
risk prediction by hsCRP after adjustment for 
traditional risk factors. For instance, a large cohort 
study of participants of the sixth examination 
cycle of the Framingham Offspring Study failed 
to ﬁ  nd any predictive value of hsCRP for ﬁ  rst 
major cardiovascular events (Wang and others, 130
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2006), and further studies based on earlier cohorts 
of the Framingham Heart Study and the Athero-
sclerosis Risk in Communities (ARIC) study 
found only a moderate incremental value in risk 
prediction of CRP after adjustment for traditional 
risk factors (Wilson and others, 2005; Folsom and 
others, 2006). Blankenberg and Danesh provided 
evidence along this line from another observa-
tional study that suggest only a moderate relative 
risk for future cardiovascular events for those in 
highest third of CRP levels (Danesh and others, 
2004; Blankenberg and others, 2006). In a recent 
effort to assess the current evidence basis for 
recommendation of measurement of hsCRP levels 
for CVD risk assessment, the Centers for Disease 
Control and Prevention and the American Heart 
Association came to the conclusion that determi-
nation of hsCRP levels appears reasonable as an 
adjunct approach to reﬁ  ning of risk stratiﬁ  cation 
in people deemed at intermediate risk by means 
of traditional risk factors. This report also 
included a recommendation of cut-off points of 
CRP levels to be used in the clinical arena, 
with values 1 mg/L indicating low risk and 
values 3 mg/L suggesting high risk (Pearson 
and others, 2003).
Elevated hsCRP levels have been consistently 
observed in smokers in various cross-sectional 
(Das, 1985) and case-control studies. For instance, 
Rohde and colleagues embarked on a cross-
sectional study amongst subjects recruited by the 
Phycicians’ Health Study and found that plasma 
CRP levels are signiﬁ  cantly associated with smok-
ing in a stepwise manner with the number of 
cigarettes smoked per day correlating with CRP 
levels (Rohde and others, 1999). Mendall and 
colleagues conﬁ  rmed this ﬁ  nding in another cross-
sectional study showing an independent positive 
correlation between smoking status and CRP lev-
els (Mendall and others, 1996). No direct asso-
ciation between the numbers of cigarettes smoked 
per day and CRP levels was found in a cross-
sectional study conducted by Tracy and colleagues 
among an elderly cohort of the Cardiovascular 
Health Study, although there was a strong correla-
tion between lifetime exposure to cigarette smoke 
and CRP (Tracy and others, 1997). It is notewor-
thy that the association between CRP and pack-
years of smoking remained signiﬁ  cant even in 
individuals who had stopped smoking for 30 years 
or more. This ﬁ  nding suggests that the inﬂ  ammatory 
cascade elicited by CS might persist even in the 
absence of the original insult. Kuller and colleagues 
conducted a case-control study using serum 
samples from participants of the Multiple Risk 
Factor Intervention Trial (MRFIT) (Anonymous, 
1982) and found a signiﬁ  cant association between 
plasma CRP levels and subsequent cardiac mortal-
ity. Of note, this association proved to be consid-
erably stronger when analysis was restricted to 
smokers (Kuller and others, 1996). A Swedish 
cross-sectional study that investigated the relation-
ship between CRP, sub-clinical atherosclerosis 
and various cardiovascular risk factors found CS 
consumption to be the variable that showed the 
strongest association with CRP levels (Hulthe and 
others, 2001).
In summary, these results suggest that by 
mediating as yet unidentiﬁ  ed insults, CS con-
sumption causes a chronic state of inﬂ  ammation 
that might be directly related to subsequent 
elevated risk for cardiovascular diseases. Future 
prospective population-based studies will bring 
clarity to the partially inconsistent ﬁ  ndings on 
the predictive value of hsCRP for cardiovascular 
events in the absence of traditional lipid-related 
risk factors. The Justiﬁ  cation for the Use of 
Statins in Primary Prevention: An Intervention 
Trial Evaluating Rosuvastatin (JUPITER), a large 
long-term double-blind placebo-controlled inter-
vention study, is currently under way to reliably 
assess whether people considered healthy by 
conventional criteria, but showing signs of 
inﬂ  ammation as assessed by plasma hsCRP lev-
els, would beneﬁ  t from statin therapy (Mora and 
Ridker, 2006). Conﬁ  rmation of reduction of risk 
for CVD-related events by lowering of plasma CRP 
in people lacking elevated LDL levels will provide 
rigorous proof of the notion that inﬂ  ammation has 
a leading and causative role to play in promoting 
CVD, and will pave the way for development of 
improved risk stratiﬁ  cation algorithms in the set-
ting of primary prevention that more profoundly 
acknowledge the association of a pro-inﬂ  ammatory 
state with an elevated risk for cardiac events.
Linking Cigarette Smoke 
Consumption to Inﬂ  ammation
The population-based studies described in the 
chapter above make a strong case for a pro-
inﬂ  ammatory state in smokers. However, the 
initial pathophysiological mechanism respon-
sible for instigation of pro-inflammatory 131
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signalling events by CS constituents has not been 
characterized. In the course of research carried 
out by our group in the past years, we could show 
that metal-catalysed protein oxidation constitutes 
a central pathway of CS-mediated endothelial 
cell damage in vitro and corroborated this result 
by a cross-sectional study involving young 
smokers (Bernhard and others, 2005; Bernhard 
and others, 2006; Bernhard and Wang, 2007). 
Extension of this ﬁ  nding came from a Finnish 
study that found body iron stores correlating 
with levels of cholesterol oxidation products 
(Tuomainen and others, 2003) and risk for myo-
cardial infarction (Salonen and others, 1992). A 
chronic state of oxidative stress generated by 
repeated deposition of metals in the vascular 
wall (bu-Hayyeh and others, 2001) might serve 
as a mechanistic link between the pro-oxidant 
and pro-inﬂ  ammatory state observed in smokers 
(Bernhard and Wang, 2007). The pro-inﬂ  ammatory 
state would in turn further aggravate the pro-
oxidant state and vice versa. In this light, the 
ﬁ  nding of elevated inﬂ  ammatory markers among 
smokers even years after smoking cessation 
further suggests that continuous deposition of 
various heavy metals present in CS and their 
persistence in the endothelial wall might serve 
as the decisive pro-inﬂ  ammatory stimulus (Tracy 
and others, 1997). Another hypothesis to explain 
the systemic pro-inﬂ  ammatory and pro-oxidative 
state in smokers suggests chronic bronchitis, a 
condition commonly observed in smokers, to be 
the decisive source of persistent pro-inﬂ  amma-
tory signalling events. For instance, a Finnish 
study demonstrated ischemic heart disease mor-
bidity to be associated with morbidity due to 
respiratory bronchitis by showing that the pres-
ence of symptoms of respiratory disease predicts 
risk for ischemic heart disease (Koskela and 
others, 2005). Conﬁ  rmation of this result came 
from another Finnish study that examined the 
predictive ability of the presence of symptoms 
of chronic bronchitis for risk of ﬁ  rst coronary 
events. The authors found that symptoms of 
chronic bronchitis predict risk for coronary dis-
ease independently from other risk factors 
(Jousilahti and others, 1996). In summary, it 
remains to be established whether chronic bron-
chitis as induced by oxidative damage of the 
bronchi and alveoli by metals and ROS present 
in CS (Bernhard and others, 2005) or direct 
deposition of heavy metals within the vascular 
wall serves as the decisive pro-inﬂ  ammatory 
stimulus in smokers.
Cigarette Smoke Consumption 
and Oxidative Stress: Role of Lipid 




A lipid parameter that has been suggested as an 
index for oxidative stress is the group of choles-
terol oxidation products. Oxysterols are increas-
ingly being recognized as potential causative 
agents in the development of atherosclerosis and 
have been shown to exert potent and diverse pro-
inﬂ  ammatory and pro-ﬁ  brotic effects on the vas-
cular wall (Leonarduzzi and others, 2002; 
Leonarduzzi and others, 2005). However, the 
overall literature on the issue as to whether 
increased plasma levels of oxysterols are associ-
ated with an increased risk for atherosclerosis 
contains equivocal reports. For instance, among 
more than 30 parameters assessed, Salonen and 
colleagues identiﬁ  ed serum levels of 7β-hydroxy-
cholesterol as the strongest predictor of a 3-year 
increase in carotid wall thickness (Salonen and 
others, 1997), while another study failed to ﬁ  nd 
any association between 7-ketocholesterol and 
peripheral vascular disease (Dyer and others, 
1997). On the other hand, indirect evidence in 
favour of a role of 7β-hydroxycholesterol in pro-
moting atherogenesis comes from a study carried 
out by Ziedén and colleagues investigating the 
mechanism underlying the epidemiological obser-
vation that Lithuanian men have a 4-fold higher 
risk for CVD than their Swedish counterparts 
despite the presence of a similar pattern of tradi-
tional risk factors in both populations, as they 
found higher levels of 7β-hydroxycholesterol in 
the Lithuanian population (Zieden and others, 
1999). Further support for the view that oxysterols 
are related to atherosclerosis comes from data 
provided by Yasunobu and colleagues showing a 
positive correlation between oxysterols and coro-
nary artery stenosis (Yasunobu and others, 2001) 
in patients undergoing coronary angiography. Of 
note, this study found no correlation between 
smoking status and circulating levels of oxyster-
ols. Elevated serum levels of oxysterols have, 132
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however, been observed in smokers (Mol and 
others, 1997) in the course of another study.
In summary, it seems that the issue of whether 
smoking is associated with increased oxysterol 
levels and whether elevated levels of oxysterols 
contribute to adverse clinical outcomes cannot be 
reliably judged on the basis of the data available 
so far, and remains to be addressed in future 
population-based studies.
F2-isoprostanes
The most recent index of ongoing lipid peroxida-
tion was provided by the identiﬁ  cation of F2-
prostaglandin isomers (F2-isoprostanes) as free 
radical-mediated oxidative degradation products 
of arachidonic acid (Morrow and others, 1990; 
Roberts and Morrow, 1994; Lawson and others, 
1999) produced independently of cyclooxygen-
ases. Of note, endogenous production of isopros-
tanes can be reliably assessed non-invasively by 
measuring their excretion in urine (Awad and 
others, 1993). As for oxysterols, a variety of pro-
atherogenic activities of F2-isoprostanes have been 
described including vasoconstriction and activation 
of platelets and monocytes (for review see (Patrono 
and FitzGerald, 1997)), which suggests that, 
besides reﬂ  ecting the degree of oxidation, these 
types of compounds might also have the ability to 
translate oxidative stress into atherogenic processes 
in the vascular wall. Increased urinary excretion 
of 8-iso-PGF2α has been shown in the context of 
various cardiovascular disease states that have been 
associated with oxidative damage such as coronary 
occlusion/reperfusion injury (Delanty and others, 
1997), diabetes mellitus (Davi and others, 1999) 
and cigarette smoking (Morrow and others, 1995; 
Reilly and others, 1996). Comparing the urinary 
excretion rate and serum levels of free and esteri-
ﬁ  ed F2-isoprostanes in 10 smokers with those of 
10 non-smokers, Morrow and colleagues found 
that urinary excretion rate as well as serum levels 
of F2-isoprostanes were signiﬁ  cantly higher in 
smokers as opposed to their non-smoking counter-
parts. Of note, both the free and esteriﬁ  ed serum 
prostanoids dropped to signiﬁ  cantly lower levels 
upon 2 weeks of smoking cessation (Morrow and 
others, 1995). Conﬁ  rmation and extension of these 
results comes from a study conducted by Reilly 
and colleagues in which the authors provide evi-
dence for a signiﬁ  cantly higher urinary excretion 
of F2-isoprostanes in smokers compared to 
non-smokers (Reilly and others, 1996). In agreement 
with the study of Morrow, abstinence from smok-
ing resulted in a signiﬁ  cant decrease in urinary 
prostanoid excretion although the levels did not 
reach those of the non-smoking controls. More-
over, administration of vitamin C alone or in com-
bination with vitamin E, but not vitamin E alone, 
proved to be an efﬁ  cient strategy to combat the 
increased isoprostane levels, as a drop in urinary 
isoprostane secretion by an average of 29% was 
achieved. Similarly, a more recent study found 
signiﬁ  cantly elevated isoprostane levels in serum, 
plasma and urine of smokers, and a rapid drop of 
the oxidation products in all of these three compart-
ments upon cessation of smoking (Pilz and others, 
2000). These studies underscore the validity of the 
notion that an imbalance of oxidants and anti-
oxidants is operative in smokers. However, the role 
of isoprostanes in cardiovascular risk prediction in 
relation to conventional risk factors has not been 
investigated as yet and awaits clariﬁ  cation in future 
clinical studies.
Cigarette smoke consumption 
and formation of oxLDL molecules
Elevated levels of circulating oxLDL molecules 
have been shown to correlate with various clinical 
manifestations of atherogenesis including manifest 
CVD, though prognostic studies assessing the 
predictive abilities of oxLDL for a deﬁ  ned clinical 
endpoint are sparse and contradictory. For instance, 
Wallenfeldt and colleagues examined the predic-
tive ability of oxLDL for progression of intima-
media-thickness (IMT) and carotid plaque 
formation in a sample of 326 initially healthy sub-
jects over 3 years of follow-up (Wallenfeldt and 
others, 2004). The authors came to conclusion that 
plasma levels of oxLDL at baseline signiﬁ  cantly 
predict both of these clinical parameters even when 
adjusted for conventional risk factors.
In a prospective study within the setting of 
secondary prevention, Shimada and colleagues also 
showed that levels of oxLDL independently predict 
future cardiac events in patients with documented 
coronary artery disease (Shimada and others, 
2004). In agreement with these results, Meisinger 
and colleagues reported on a nested case-control 
study among participants in the MONICA project, 
in the course of which the authors identiﬁ  ed oxLDL 
as a signiﬁ  cant predictor for future coronary events 
in initially healthy people (Meisinger and others, 133
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2005). However, the largest prospective study on 
the prognostic value of oxLDL for coronary artery 
disease in apparently healthy people seriously 
questioned these results on the basis of the ﬁ  nding 
that the calculated relative risk associated with 
elevated oxLDL levels loses statistical signiﬁ  cance 
after adjustment for standard risk factors. The 
authors found that oxLDL failed to give prognos-
tic information beyond that provided by apolipo-
protein B and the total cholesterol/HDL-C ratio, 
whereas the latter parameters remained signiﬁ  cant 
predictors for risk for cardiac events when adjusted 
for oxLDL (Wu and others, 2006). This result 
evidently challenges an independent contributory 
action of oxLDL to CVD development, and sug-
gests that oxLDL rather serves as a surrogate 
parameter for apolipoprotein B and total LDL 
levels.
Circulating oxLDL molecules have been 
observed to be elevated in smokers by means of 
cross-sectional studies (Fickl and others, 1996; Liu 
and others, 2000). However, further studies are 
needed to establish whether measurement of cir-
culating oxLDL levels indeed augments our current 
predictive capabilities beyond that achievable by 
consideration of conventional risk factors, and 
whether therapies tailored to combat oxLDL levels 
are justiﬁ  ed.
Cigarette smoke consumption 
and formation of protein
oxidation products
In contrast to the plentiful literature examining the 
utility of lipid peroxidation products as quantitative 
indices for oxidative stress, oxidative protein 
modiﬁ  cations in human plasma have been only 
sparsely investigated as potential biomarkers of 
oxidative damage. Proteins are, however, ﬁ  rmly 
recognized as major targets of oxidative attack 
in vivo (Stadtman and Oliver, 1991). This knowledge, 
coupled with the long half-life of some proteins 
that enables accumulation of a certain oxidation 
product over time, suggests that protein oxidation 
products have the potential to serve as reliable and 
sensitive markers for oxidative stress (Dean and 
others, 1997). As reviewed in great detail by Davis 
and colleagues (Davies and others, 1999), radicals 
can give rise to an array of protein oxidation prod-
ucts that differ in their individual utility as 
biomarkers for oxidative damage for various bio-
chemical reasons. Some of these compounds 
such as 3,4-dihydroxyphenyalanine (DOPA) or 
di-tyrosine have been found at an increased level 
in advanced human atherosclerotic plaques (Fu and 
others, 1998). However, a detailed understanding 
of the nature of the different protein oxidation 
products and appropriate methods for their detec-
tion have only been developed recently, and there-
fore studies examining the association of certain 
protein oxidation products with pathophysiological 
endpoints relevant for CVD are sparse. As against 
this, the quantiﬁ  cation of protein carbonyl forma-
tion as a generic marker for oxidative modiﬁ  cations 
of protein side-chains has been used for quite a 
while and is widely recognized as a valid approach 
to assess the overall extent of protein oxidation 
(Stadtman and others, 1992). Using this technique, 
we conﬁ  rmed in a recent study that oxidative dam-
age takes place in endothelial cells subjected to CS 
in vitro (Schmieder and others, 2006). In an in vivo 
study, increased protein carbonyl formation was 
shown in the plasma of smokers (Pignatelli and 
others, 2001).
Another marker of oxidative damage that has 
been associated with chronic inﬂ  ammatory disor-
ders is generated by nitration of tyrosine residues 
of proteins (Kaur and Halliwell, 1994). 3-Nitroty-
rosine is created in the presence of nitrating agents 
(such as peroxynitrite, a major radical present in 
CS) and may hence be an especially promising 
candidate marker to assess the extent of oxidative 
damage in smokers. Moreover, since the nitration 
reaction of tyrosine is irreversible, 3-nitrotyrosine 
levels might provide an integrative summary of 
cumulative protein damage acquired over a certain 
time frame. 3-Nitrotyrosine levels have been 
shown to be signiﬁ  cantly elevated in plasma, in 
the apolipoprotein B part of isolated LDL mole-
cules as well as in the vascular tissue of smokers 
(Petruzzelli and others, 1997; Beckman and others, 
2004; Yamaguchi and others, 2005). The hypoth-
esis that peroxynitrite of CS is decisively involved 
in mediating oxidative damage has also been con-
ﬁ  rmed in vitro by the detection of 3-nitrotyrosine 
formation in LDL particles exposed to CSE (Yama-
guchi and others, 2002). Discussing the clinical 
consequences of elevated 3-nitrotyrosine levels, 
Shishehbor and colleagues embarked on a case-
control study to evaluate its predictive power for 
the presence of CVD, and found, after adjustment 
for the Framingham criteria and plasma CRP lev-
els, a signiﬁ  cantly higher odds ratio for coronary 
heart disease in the upper quartiles of 3-nitrotyrosine 134
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levels compared to the lowest quartile (Shishehbor 
and others, 2003).
Overall, it would appear that the pattern of pro-
tein carbonyl or 3-nitrotyrosine formation provides 
a reliable footprint of accumulated oxidative dam-
age, and the evidence on protein oxidation with 
regard to CS consumption is in line with the concept 
of a pro-oxidant state of smokers as identiﬁ  ed by 
measurement of lipid peroxidation products. More-
over, preliminary data suggest that oxidative protein 
damage by nitric oxide-derived radicals might be 
a contributing factor to cigarette smoke-induced 
atherogenesis (Shishehbor and others, 2003).
Cigarette Smoke Consumption
and Soluble Adhesion Molecules
Recently, increasing information on the ability of 
soluble adhesion molecules to reﬂ  ect and promote 
CVD from both basic and clinical studies has 
become available, and plasma levels of adhesion 
molecules have been suggested to serve as promis-
ing candidate markers for the risk for developing 
atherosclerosis and associated complications 
(Mulvihill and others, 2002; Blankenberg and 
others, 2003). Several population-based studies 
indeed provided evidence for a predictive ability 
of certain types of adhesion molecules for severity 
of ongoing atherosclerosis and risk for cardiac 
events. The Atherosclerosis Risk in Communities 
(ARIC) study provided the ﬁ  rst evidence basis in 
support of the concept that adhesion molecules 
serve as novel independent biomarkers for athero-
sclerosis by showing that sICAM but not sVCAM 
levels predict risk for incident coronary heart dis-
ease (CHD) after adjustment for traditional athero-
sclerosis risk factors (Hwang and others, 1997). 
Notably, this study found signiﬁ  cantly higher lev-
els of sICAM in smokers and a strong correlation 
between sICAM and years of cigarette smoking. 
This ﬁ  nding extends to the in vivo situation the 
in vitro-based data previously delivered by Kalra 
and colleagues who found elevated ICAM-1 
expression in HUVEC treated with CS condensate 
(Kalra and others, 1991). Further clinical studies 
in support of a predictive value of sICAM with 
regard to CVD-related endpoints came from Rid-
ker and colleagues who embarked on a nested 
case-control study using data from the Physicians’ 
Health Study and found sICAM to predict future 
myocardial infarction independently of classical 
risk factors (Ridker and others, 1998c). Of note, 
also this study found signiﬁ  cantly higher sICAM 
levels in smokers as compared to non-smokers. A 
cross-sectional analysis of an array of markers of 
inflammation in participants of the Women’s 
Health Study conducted by Bermudez and col-
leagues found circulating levels of various inﬂ  am-
matory markers including hsCRP, IL-6, sICAM 
and P-selectin to be signiﬁ  cantly elevated in smok-
ers (Bermudez and others, 2002). Notably, levels 
of all inﬂ  ammatory markers increased in parallel 
with higher degrees of smoking exposure. Statisti-
cal signiﬁ  cance of all markers but P-selectin was 
maintained after adjustment for conventional lipid- 
and non-lipid-associated CVD risk factors. Another 
case-control study involving participants from the 
Women’s Health Study found a signiﬁ  cant asso-
ciation between elevated soluble P-selectin levels 
and CS consumption (Ridker and others, 2001a). 
In this study, the predictive ability of P-selectin for 
future cardiac events attained statistical signiﬁ  -
cance even after adjustment for classical risk fac-
tors. This result extrapolates to the in vivo setting 
our own in vitro ﬁ  nding of a shedding of P-selectin 
into cell culture medium from HUVEC exposed 
to CS (Bernhard and others, 2005). Further evi-
dence in support of pro-adhesive events elicited in 
the vascular wall by CS constituents has been 
provided by Mazzone and colleagues who found 
sICAM and sVCAM to be signiﬁ  cantly elevated 
in hypertensive smokers as compared to non-
smoking hypertensive patients (Mazzone and oth-
ers, 2001), a ﬁ  nding that further underlines the 
independence of smoking from other known risk 
factors for CVD. Blann and colleagues performed 
a cross sectional study on inﬂ  ammatory markers 
in regular smokers and found soluble von Wille-
brand factors (svWf), sICAM and sP-selectin to 
be signiﬁ  cantly elevated amongst the smokers 
(Blann and others, 1997). Remarkably, sICAM and 
sP-selectin dropped to signiﬁ  cantly lower levels 
after a 6-week smoking cessation.
In summary, there is a consistent association 
between CS consumption and elevated sICAM 
levels. This ﬁ  nding is of particular interest as it 
highlights a boost of pathophysiological processes 
that are at play at the earliest stages of atherogen-
esis in people consuming CS. An up-scaling of 
inﬂ  ammatory processes in the vascular wall by 
CS-derived compounds by their acting as a stress 
factor to endothelial cells appears to be a plausible 
mechanistic link between smoking and accelerated 
atherogenesis.135
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Conclusion
CS consumption remains a signiﬁ  cant factor in 
the development of atherosclerosis, the associated 
complications of which exact as large a toll on 
health and life of human populations as no other 
disease currently afﬂ  icting mankind. CS con-
sumption has been correlated, using cross-
sectional as well as prospective case-control 
studies, with elevated levels of biomarkers for 
oxidative stress such as isprostanes, oxysterols 
and oxLDL molecules, and inﬂ  ammatory markers 
including hsCRP, IL-6 and soluble adhesion 
molecules. Our ﬁ  nding of increased levels of 
heavy metals in the serum of young smokers 
deﬁ  nes an additional biomarker that is elevated 
in smokers. These data support our working 
hypothesis of CS-induced atherosclerosis, namely 
that oxidative stress generated by Fenton-like 
catalytic reactions between ROS and the high 
content of heavy metals present in CS is operative 
in people exposed to CS (Fig. 1). However, as has 
been described in the chapters above, although 
Statins ROS, Metals N-acetyl cystein (NAC)
Lipid oxidation, protein oxidation, vascular deposition of metals
Increased levels of F2-isoprostanes, oxysteroles, oxLDL molecules,
protein carbonyl formation, serum cadmium and strontium levels
Damage of alveoli and bronchi
Statins Inflammation Endothelial cell damage
- shedding of adhesion molecules
- cell contraction coupled with loss of microtubules





Increased risk for CVD
Figure 1. Smoking leads to oxidative damage of lipids and proteins with each drag of CS inhaled. At the same time, heavy metals enter the 
blood via the lungs and are deposited within the vascular wall. Metal-catalysed oxidation reactions lead to a systemic pro-inﬂ  ammatory state 
that is associated with an increased risk for cardiovascular events. A measure of the inﬂ  ammatory state can be obtained by assessing cir-
culating hsCRP, IL-6, ICAM and P-selectin levels. Furthermore, markers that serve as a direct footprint of the extent of overall lipid and 
protein damage are amenable to CVD risk assessment. The pro-inﬂ  ammatory cascade of events might be abrogated by either combating 
inﬂ  ammation by means of metal chelating agents such as NAC, or by compounds that target the pro-inﬂ  ammatory response to the insult 
imposed by CS such as statins. The latter group of drugs also has anti-oxidative properties, and thus might prove to be effective in particu-
lar against smoking-mediated CVD.
All the markers depicted in the graph have been shown to be present at an increased level in the blood of smokers. The markers presented 
in bold have been shown to predict risk for future CVD independent of conventional risk factors.136
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there is a large body of evidence pointing to 
elevated levels of various markers of oxidative 
stress in smokers, prospective studies on the pre-
dictive value of these markers for clinical cardio-
vascular endpoints are sparse and have yielded 
inconsistent results. At the same time, studies that 
have been undertaken so far to analyse the effects 
of antioxidant supplementation as a preventive 
measure in smokers concluded with partially 
equivocal results. Given that the blood concentra-
tion achievable by supplementation with the 
antioxidants administered has not been tested in 
most cases, and their long-term impact on end-
points of clinical relevance has not been evalu-
ated, caution is needed in the interpretation of 
these results. Thus, it would be wrong to conclude 
that oxidative stress does not play a major role in 
smoking-mediated CVD. The approach of apply-
ing pure anti-oxidants neglects our ﬁ  nding of 
increased levels of heavy metals as a potential 
source of ROS in smokers as metals are not tar-
geted by the vitamins studied. Interventional 
studies applying metal chelating agents that focus 
on clearly deﬁ  ned cardiovascular endpoints are 
urgently needed to make a ﬁ  nal verdict on the 
value of these compounds as a preventive strategy 
for CVD in smokers. Potential candidate com-
pounds appear to be sulphuric compounds such 
as N-acetylcysteine that has already been shown 
by us to partially inhibit CS-induced endothelial 
cell damage in vitro (Bernhard and others, 2005). 
Another therapeutic option one might want to 
consider is administration of a low-dose statin 
regimen, given the ﬁ  nding that statins have the 
ability to combat oxidative stress and inﬂ  amma-
tion concomitantly even at moderate doses that 
do not inﬂ  uence the blood lipid pattern.
In summary, there is no doubt about the multi-
factorial background of CS-induced atherogenesis, 
and the relative contributions of inﬂ  ammation and 
oxidative stress to this phenomenon still remain 
to be clariﬁ  ed. However, the pro-atherogenic lines 
of events are not mutually exclusive, with 
inflammation causing oxidative stress and 
vice versa. Furthermore, preliminary evidence 
points to a protective action of compounds that 
combat both inﬂ  ammation and oxidative stress 
such as statins. It would thus appear that as a pri-
mary prevention strategy against CVD, we have 
some promising tools at hand. Long-term inter-
ventional trials are warranted for examining in 
detail their efﬁ  cacy.
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